Xanthatin Induces G2/M Cell Cycle Arrest and Apoptosis in Human Gastric Carcinoma MKN-45 Cells

 

 Buy Article Permissions and Reprints

Abstract

Xanthatin, a natural bioactive compound of sesquiterpene lactones, was isolated and purified from air-dried aerial part of Xanthium sibiricum Patrin ex Widder. In the present study, we demonstrated the significant antiproliferative and proapoptotic effects of xanthatin on human gastric carcinoma MKN-45 cells. MTS assay showed that xanthatin produced obvious cytotoxicity in MKN-45 cells with IC₅₀ values of 18.6, 9.3, and 3.9 µM for 12, 24, and 48 h, respectively. Results of flow cytometry analysis indicated that the antiproliferative activity induced by xanthatin might be executed via G2/M cell cycle arrest and proapoptosis in MKN-45 cells. Western blot analysis elucidated that: a) xanthatin downregulated expression of Chk1 and Chk2 and phosphorylation of CDC2, which are known as key G2/M transition regulators; b) xanthatin increased p53 activation, decreased the bcl-2/bax ratio and the levels of downstream procaspase-9 and procaspase-3, which are key regulators in the intrinsic apoptosis pathway; c) xanthatin blocked phosphorylation of NF-κB (p65 subunit) and of IκBα, which might contribute to its proapoptotic effects on MKN-45 cells. In conclusion, our results suggest that xanthatin may have therapeutic potential against human gastric carcinoma.

^* These two authors contributed equally to this work.

• References

• 1 Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894-901
  CrossrefPubMedGoogle Scholar
• 2 Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol 2011; 4: 687-699
  CrossrefPubMedGoogle Scholar
• 3 Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials?. Drug Discov Today 2010; 15: 668-678
  CrossrefPubMedGoogle Scholar
• 4 Zhang S, Won YK, Ong CN, Shen HM. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 2005; 5: 239-249
  CrossrefPubMedGoogle Scholar
• 5 Christensen SB, Skytte DM, Denmeade SR, Dionne C, Moller JV, Nissen P, Isaacs JT. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Medicinal Chem 2009; 9: 276-294
  PubMedGoogle Scholar
• 6 Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate 2009; 69: 827-837
  CrossrefPubMedGoogle Scholar
• 7 Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci 2005; 78: 431-441
  CrossrefPubMedGoogle Scholar
• 8 Vasas A, Hohmann J. Xanthane sesquiterpenoids: structure, synthesis and biological activity. Nat Prod Rep 2011; 28: 824-842
  CrossrefPubMedGoogle Scholar
• 9 Little JE, Foote MW, Johnstone DB. Xanthatin: an antimicrobial agent from Xanthium pennsylvanicum . Arch Biochem 1950; 27: 247-254
  PubMedGoogle Scholar
• 10 Roussakis C, Chinou I, Vayas C, Harvala C, Verbist JF. Cytotoxic activity of xanthatin and the crude extracts of Xanthium strumarium . Planta Med 1994; 60: 473-474
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Ramirez-Erosa I, Huang Y, Hickie RA, Sutherland RG, Barl B. Xanthatin and xanthinosin from the burs of Xanthium strumarium L. as potential anticancer agents. Can J Physiol Pharmacol 2007; 85: 1160-1172
  CrossrefPubMedGoogle Scholar
• 12 Kovacs A, Vasas A, Forgo P, Rethy B, Zupko I, Hohmann J. Xanthanolides with antitumour activity from Xanthium italicum . Z Naturforsch C 2009; 64: 343-349
  PubMedGoogle Scholar
• 13 Takeda S, Matsuo K, Yaji K, Okajima-Miyazaki S, Harada M, Miyoshi H, Okamoto Y, Amamoto T, Shindo M, Omiecinski CJ, Aramaki H. (−)-Xanthatin selectively induces GADD45gamma and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells. Chem Res Toxicol 2011; 24: 855-865
  CrossrefPubMedGoogle Scholar
• 14 Penissi AB, Vera ME, Mariani ML, Rudolph MI, Cenal JP, de Rosas JC, Fogal TH, Tonn CE, Favier LS, Giordano OS, Piezzi RS. Novel anti-ulcer alpha,beta-unsaturated lactones inhibit compound 48/80-induced mast cell degranulation. Eur J Pharmacol 2009; 612: 122-130
  CrossrefPubMedGoogle Scholar
• 15 Zhang W, Han W, Li Y, Zhang S, Zhao D. [Chemical constituents from Xanthium mongolicum]. Zhongguo Zhong Yao Za Zhi 2009; 34: 1687-1689
  PubMedGoogle Scholar
• 16 Brower V. Back to nature: extinction of medicinal plants threatens drug discovery. J Natl Cancer Inst 2008; 100: 838-839
  CrossrefPubMedGoogle Scholar
• 17 Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Droge W, Schmitz ML. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 1998; 273: 1288-1297
  Google Scholar
• 18 Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007; 10: 13-29
  CrossrefPubMedGoogle Scholar
• 19 Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3: 513-519
  PubMedGoogle Scholar
• 20 Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 2006; 6: 308-317
  CrossrefPubMedGoogle Scholar
• 21 Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429
  CrossrefPubMedGoogle Scholar
• 22 Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98: 523-528
  CrossrefPubMedGoogle Scholar
• 23 Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A. The E2F1/Rb and p 53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol 2010; 20: 258-266
  CrossrefPubMedGoogle Scholar
• 24 Sarkar FH, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008; 13: 2950-2959
  CrossrefPubMedGoogle Scholar
• 25 Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009; 8: 3267-3273
  CrossrefPubMedGoogle Scholar
• 26 Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23: 9394-9407
  CrossrefPubMedGoogle Scholar

• Supplementary Material